Literature DB >> 11823954

Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?

David M Livermore1.   

Abstract

Pseudomonas aeruginosa carries multiresistance plasmids less often than does Klebsiella pneumoniae, develops mutational resistance to cephalosporins less readily than Enterobacter species, and has less inherent resistance than Stenotrophomonas maltophilia. What nevertheless makes P. aeruginosa uniquely problematic is a combination of the following: the species' inherent resistance to many drug classes; its ability to acquire resistance, via mutations, to all relevant treatments; its high and increasing rates of resistance locally; and its frequent role in serious infections. A few isolates of P. aeruginosa are resistant to all reliable antibiotics, and this problem seems likely to grow with the emergence of integrins that carry gene cassettes encoding both carbapenemases and amikacin acetyltransferases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11823954     DOI: 10.1086/338782

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  352 in total

1.  Effects of sequential and simultaneous applications of bacteriophages on populations of Pseudomonas aeruginosa in vitro and in wax moth larvae.

Authors:  Alex R Hall; Daniel De Vos; Ville-Petri Friman; Jean-Paul Pirnay; Angus Buckling
Journal:  Appl Environ Microbiol       Date:  2012-06-01       Impact factor: 4.792

2.  Frequency of spontaneous resistance to fosfomycin combined with different antibiotics in Pseudomonas aeruginosa.

Authors:  Alexandro Rodríguez-Rojas; Alejandro Couce; Jesús Blázquez
Journal:  Antimicrob Agents Chemother       Date:  2010-08-16       Impact factor: 5.191

3.  Genes involved in copper resistance influence survival of Pseudomonas aeruginosa on copper surfaces.

Authors:  J Elguindi; J Wagner; C Rensing
Journal:  J Appl Microbiol       Date:  2009-02-23       Impact factor: 3.772

4.  Development and Assessment of Risk Scores for Carbapenem and Extensive β-Lactam Resistance Among Adult Hospitalized Patients With Pseudomonas aeruginosa Infection.

Authors:  Sara Y Tartof; Jennifer L Kuntz; Lie H Chen; Rong Wei; Laura Puzniak; Yun Tian; Theresa M Im; Harpreet S Takhar; Sanjay Merchant; Thomas Lodise
Journal:  JAMA Netw Open       Date:  2018-10-05

5.  A review of the Royal Perth Hospital Bali experience: an infection control perspective.

Authors:  Christopher H Heath; C Terri Orrell; Rosie Ce Lee; John W Pearman; Cheryll McCullough; Keryn J Christiansen
Journal:  Aust Infect Control       Date:  2016-03-17

6.  Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation.

Authors:  B Henrichfreise; I Wiegand; W Pfister; B Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191

7.  β-Lactam selectivity of multidrug transporters AcrB and AcrD resides in the proximal binding pocket.

Authors:  Naoki Kobayashi; Norihisa Tamura; Hendrik W van Veen; Akihito Yamaguchi; Satoshi Murakami
Journal:  J Biol Chem       Date:  2014-02-20       Impact factor: 5.157

8.  Emergence of polymyxin B resistance influences pathogenicity in Pseudomonas aeruginosa mutators.

Authors:  Zackery P Bulman; Mark D Sutton; Neang S Ly; Jurgen B Bulitta; Patricia N Holden; Roger L Nation; Jian Li; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2015-04-27       Impact factor: 5.191

9.  Isolation and identification of a Paenibacillus polymyxa strain that coproduces a novel lantibiotic and polymyxin.

Authors:  Zengguo He; Duygu Kisla; Liwen Zhang; Chunhua Yuan; Kari B Green-Church; Ahmed E Yousef
Journal:  Appl Environ Microbiol       Date:  2006-10-27       Impact factor: 4.792

10.  Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.

Authors:  V Plasencia; N Borrell; M D Maciá; B Moya; J L Pérez; A Oliver
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.